Wex Pharmaceuticals Inc.
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
- Conditions
- Chemotherapy-induced Neuropathic PainChemotherapy-induced Peripheral Neuropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Wex Pharmaceuticals Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05359133
- Locations
- 🇺🇸
Syrentis Clinical Research, Santa Ana, California, United States
🇺🇸Providence Medical Foundation, Santa Rosa, California, United States
🇺🇸MEDSOL Clinical Research Center, Port Charlotte, Florida, United States
A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Wex Pharmaceuticals Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04083833
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
- Conditions
- PainPeripheral NeuropathyNeuropathic Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Wex Pharmaceuticals Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT01655823
- Locations
- 🇺🇸
Lalita Pandit, Fountain Valley, California, United States
🇺🇸Robert Moss, Fountain Valley, California, United States
🇺🇸Alliance Research Centers, Laguna Hills, California, United States
Comparison Study of Liquid and Lyophilized Formulations of Subcutaneous Tetrodotoxin (TTX) in Healthy Volunteers
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- Wex Pharmaceuticals Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01527734
- Locations
- 🇺🇸
Comprehensive Clinical Research, Tacoma, Washington, United States
Tetrodotoxin Open-label Efficacy and Safety Continuation Study
- Conditions
- PainCancer
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- Wex Pharmaceuticals Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT00726011
- Locations
- 🇨🇦
WEX Pharmaceuticals Inc., Vancouver, British Columbia, Canada
- Prev
- 1
- 2
- Next